I am responding to your recent article, “A quality improvement project to enhance the management of hyperkalemia in hospitalized patients” [BCMJ 2012;54:27-33]. I appreciate the purpose of the article; however, I am alarmed that the authors have not updated the information regarding treatment. The use of cation exchange resins is a myth that continues to be propagated.
I remember during my own training reading textbooks and being told by senior residents and attending staff physicians how important the use of cation exchange resins were to reduce the overall serum potassium level. This evidence is based on two studies in the NEJM from 1961. These studies are incredibly flawed and would not be worthy of the wastepaper basket within a NEJM office washroom today.
The first by Scherr and colleagues looked at 32 patients with acute or chronic renal failure with hyperkalemia. Twenty to 60 grams of resin plus cathartic was administered as needed. Most patients also received glucose and insulin and some received bicarbonate. All of these patients were placed on low potassium diets and there were no controls. Twenty-three of the 30 patients (two patients were never mentioned again) had a decrease of 0.4 mEq/L in their serum potassium in the first 24 hours. No statistical analysis was conducted.
The second study had similar distressing issues. Five patients received the resin plus sorbitol, and three patients received sorbitol only. There was once again no placebo control. All of these patients received a carbohydrate-only diet consisting of carob syrup and ginger ale. This was a zero potassium intake diet and their potassium levels were checked 5 days later.
The first group had a reduction from 6.6 to 5.2 mEq/L in their serum potassium while the second group (sorbitol only) had a reduction from 6.3 to 4.6 mEq/L. No real conclusion can be drawn from this study other than perhaps a zero potassium diet may assist in lowering serum potassium over 5 days.
In 1998 a study was published in the Journal of American Society of Nephrologists entitled “Effect of single dose resin-cathartic therapy on serum potassium concentration in patients with end-stage renal disease.” This study had a sequential study design where different therapies were provided to each end-stage renal disease patient.
The first stage measured serum potassium after a placebo, then serum potassium was measured at 4, 8, and 12 hours after administering 30 grams of Kaexylate, then again at 4, 8, and 12 hours after 30 grams of Kaexylate with sorbitol. There was no statistical difference in potassium levels between any of the groups at hours 4, 8, and 12.
Perhaps another study needs to be conducted that is more robust and answers this question definitively. I, however, have stopped using cation exchange resins in any form. I simply utilize the other therapies listed in this article and treat the etiology of the hyperkalemia. Most commonly this involves stopping the offending medication. If dilution and promotion of increased potassium excretion will not allow for a return of safe potassium levels, renal dialysis may be required.
Continued treatment with salbutomol, insulin +/- glucose, bicarbonate if acidotic, fluids and furosemide may need to be tailored to each clinical situation while awaiting dialysis. Cation exchange resins should not be part of this algorithm unless you find yourself back in 1961.
—J. Gord McInnes, MD, FRCPC
1. Scherr L, Ogden DA, Mead AW, et al. Management of hyperkalemia with a cation-exchange resin. N Engl J Med. 1961 Jan 19;264:115-119.
2. Flinn RB, Merrill JP, Welzant WR. Treatment of the oliguric patient with a new sodium-exchange resin and sorbitol; a preliminary report. N Engl J Med 1961 Jan 19;264:111-115.
3. Gruy-Kapral C, Emmett M, Santa Ana CA, et al. Effect of single dose resin-cathartic therapy on serum potassium concentration in patients with end-stage renal disease. J Am Soc Nephrol 1998;9:1924-1930.
Above is the information needed to cite this article in your paper or presentation. The International Committee
of Medical Journal Editors (ICMJE) recommends the following citation style, which is the now nearly universally
accepted citation style for scientific papers:
Halpern SD, Ubel PA, Caplan AL, Marion DW, Palmer AM, Schiding JK, et al. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.
About the ICMJE and citation styles
The ICMJE is small group of editors of general medical journals who first met informally in Vancouver, British Columbia, in 1978 to establish guidelines for the format of manuscripts submitted to their journals. The group became known as the Vancouver Group. Its requirements for manuscripts, including formats for bibliographic references developed by the U.S. National Library of Medicine (NLM), were first published in 1979. The Vancouver Group expanded and evolved into the International Committee of Medical Journal Editors (ICMJE), which meets annually. The ICMJE created the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals to help authors and editors create and distribute accurate, clear, easily accessible reports of biomedical studies.
An alternate version of ICMJE style is to additionally list the month an issue number, but since most journals use continuous pagination, the shorter form provides sufficient information to locate the reference. The NLM now lists all authors.
BCMJ standard citation style is a slight modification of the ICMJE/NLM style, as follows:
- Only the first three authors are listed, followed by "et al."
- There is no period after the journal name.
- Page numbers are not abbreviated.
For more information on the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, visit www.icmje.org